PHARMACOGENOMICS
PGxOneTM Plus

Over 50 genes | Over 200 variants | Over 300 drugs
A genetic test that provides insight for therapeutic decisions. Provides gene, genotype, and PGx related phenotype information. Recommendation for drugs across multiple therapeutic areas including: cardiology, pain, oncology & psychiatry

Sample Type:          Saliva
Suitable For:           All Individuals
Lab Certification:  CAP / CLIA
TAT:                          7 – 10 working days upon receipt of sample at Laboratory

AtheroGxOne™

A single test to detect mutations in 84 genes responsible for monogenic diseases of early atherosclerosis . Covered conditions include the following Premature Coronary Artery Disease, Familial Hypercholesterolemia & Familial Triglyceridemia.

Sample Type:          Saliva
Suitable for:            Individuals who want to know the risk of Premature Coronary Disease, Familial Hypercholesterolemia & Familial Triglyceridemia
Lab Certification:  CAP / CLIA
TAT:                         14 – 21 working days upon receipt of sample at Laboratory

CardioGxOne™

A comprehensive 213-gene test that assists in the differential diagnosis of over 30 inherited cardiovascular diseases and sudden cardiac death (e.g. cardiomyopathies, aortic syndromes, channelopathies & arrhythmias and more).

Sample Type:          Saliva
Suitable For:           Individuals diagnosed with cancer
Lab Certification:  CAP / CLIA
TAT:                          14 – 21 working days upon receipt of sample at Laboratory

ONCOLOGY TEST PORTFOLIO – TISSUE
OncoGxOne™ Plus

A comprehensive Next Generation Sequencing (NGS) based test that detects cancer driving mutations for targeted selection and provides tools for immunotherapy recommendation.

  • 364 genes in total, 38 sequenced from DNA & RNA
  • Somatic Mutation Detection: SNV, indel, CNV and FUSION
  • Immuno-oncology solutions for anti-PD1 Therapy recommendations: Microsatellite Instability (MSI), Tumor Mutation Burden (TMB) , HLA-typing
  • Average depth of coverage exceeds 250x resulting in mutation detection with high specificity and sensitivity

Sample Type:          Tissue
Suitable For:           Individuals diagnosed with cancer
Lab Certification:  CAP / CLIA
TAT:                          14 – 21 working days upon receipt of sample at Laboratory

OncoGxSelect™

It analyzes a patient’s tumor for genetic mutations frequently found in select cancers. This test utilizes Next Generation Sequencing (NGS) technology to detect alterations in 12 known oncogenes and is aligned with well-established molecular testing guidelines. Actionable results help guide therapeutic decisions related to targeted cancer therapy. Detects all types of mutations (SNV, gene fusion, Indel, CNV) with a high degree of accuracy. Cancer types: Non-small cell lung cancer (NSCLC), Melanoma, Thyroid, Lower GI (colorectal), Upper GI (Esophageal, GIST) & Breast.

Sample Type:          Tissue
Suitable For:           Individuals diagnosed with cancer
Lab Certification:  CAP / CLIA
TAT:                          14 – 21 working days upon receipt of sample at Laboratory

ONCOLOGY TEST PORTFOLIO – BLOOD
LiquidGx – 17 Genes

Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently mutated in cancer
Includes MSI for selection of anti-PD1 therapy. Includes detection of SNV, Fusion, CNV, INDELS and MSI. Input includes both ctDNA and ctRNA allowing for optimal fusion detection including, novel fusions.
Includes EGFR T790M and EGFR C797S variant detection for drug
Includes microsatellite instability (MSI) status for checking if a tumor will respond to anti-PD-1 therapy.
MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)

Sample Type:          Blood
Suitable For:           Individuals diagnosed with cancer
Lab Certification:  CAP / CLIA
TAT:                          5 – 7 working days upon receipt of sample at Laboratory

LiquidGx – 4 Genes

Single gene analytes via qPCR that can be run individually or multiplexed. Limit-of-detection 0.01%, the equivalent of finding one DNA fragment in 10,000.  Optimal fusion detection via ctRNA. Includes EGFR T790M and EGFR C797S variant detection for drug.

Sample Type:          Blood
Suitable For:           Individuals diagnosed with cancer
Lab Certification:  CAP / CLIA
TAT:                          5 – 7 working days upon receipt of sample at Laboratory